{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:09:16Z","timestamp":1790237356132,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.beha.2023.101469","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T04:42:42Z","timestamp":1681879362000},"page":"101469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Financial toxicity in patients with leukemia undergoing hematopoietic stem cell transplantation: A systematic review"],"prefix":"10.1016","volume":"36","author":[{"given":"Orrin","family":"Pail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9864-7413","authenticated-orcid":false,"given":"Thomas G.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.beha.2023.101469_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.amepre.2020.02.016","article-title":"Financial hardship, healthcare utilization, and health among U.S. Cancer survivors","volume":"59","author":"Zheng","year":"2020","journal-title":"Am J Prev Med"},{"issue":"5","key":"10.1016\/j.beha.2023.101469_bib2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JOP.2013.001322","article-title":"Impact of financial burden of cancer on survivors' quality of life","volume":"10","author":"Fenn","year":"2014","journal-title":"J. Oncol. Pract."},{"issue":"2","key":"10.1016\/j.beha.2023.101469_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw205","article-title":"Financial hardships experienced by cancer survivors: a systematic review","volume":"109","author":"Altice","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.beha.2023.101469_bib4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/1055-9965.EPI-19-0460","article-title":"Medical financial hardship intensity and financial sacrifice associated with cancer in the United States","volume":"29","author":"Han","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.beha.2023.101469_bib5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","article-title":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience","volume":"18","author":"Zafar","year":"2013","journal-title":"Oncol"},{"issue":"6","key":"10.1016\/j.beha.2023.101469_bib6","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1377\/hlthaff.2012.1263","article-title":"Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis","volume":"32","author":"Ramsey","year":"2013","journal-title":"Health Aff"},{"issue":"1","key":"10.1016\/j.beha.2023.101469_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13561-019-0253-7","article-title":"The long-term effects of cancer survivorship on household assets","volume":"10","author":"Pak","year":"2020","journal-title":"Health Econ Rev"},{"issue":"Suppl 11","key":"10.1016\/j.beha.2023.101469_bib8","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/cncr.28067","article-title":"Employment challenges for cancer survivors","volume":"119","author":"Mehnert","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.beha.2023.101469_bib9","doi-asserted-by":"crossref","first-page":"pky004","DOI":"10.1093\/jncics\/pky004","article-title":"Is cancer history associated with assets, debt, and net worth in the United States?","volume":"2","author":"Doroudi","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"2","key":"10.1016\/j.beha.2023.101469_bib10","first-page":"153","article-title":"The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment","volume":"68","author":"Carrera","year":"2018","journal-title":"CA A Cancer J Clin"},{"issue":"20","key":"10.1016\/j.beha.2023.101469_bib11","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1002\/cncr.28262","article-title":"Are survivors who report cancer-related financial problems more likely to forgo or delay medical care?","volume":"119","author":"Kent","year":"2013","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.beha.2023.101469_bib12","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.6004\/jnccn.2019.7305","article-title":"Financial burdens of cancer treatment: a systematic review of risk factors and outcomes","volume":"17","author":"Smith","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.beha.2023.101469_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/JOP.18.00120","article-title":"Financial toxicity in adults with cancer: adverse outcomes and noncompliance","author":"Knight","year":"2018","journal-title":"J. Oncol. Pract."},{"issue":"10","key":"10.1016\/j.beha.2023.101469_bib14","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","article-title":"Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study","volume":"2","author":"Huntington","year":"2015","journal-title":"Lancet Haematol"},{"issue":"14","key":"10.1016\/j.beha.2023.101469_bib15","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/cncr.30648","article-title":"Cost-related medication nonadherence among adolescent and young adult cancer survivors","volume":"123","author":"Kaul","year":"2017","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.beha.2023.101469_bib16","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/cncr.30560","article-title":"Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States","volume":"123","author":"Zheng","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2023.101469_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/EDBK_100019","article-title":"Financial toxicity and equitable access to clinical trials","volume":"39","author":"Chino","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"8","key":"10.1016\/j.beha.2023.101469_bib18","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1634\/theoncologist.2019-0146","article-title":"Addressing the financial burden of cancer clinical trial participation: longitudinal effects of an equity intervention","volume":"24","author":"Nipp","year":"2019","journal-title":"Oncol"},{"key":"10.1016\/j.beha.2023.101469_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105196","article-title":"Association of significant financial burden with survival for head and neck cancer patients treated with radiation therapy","volume":"115","author":"Ma","year":"2021","journal-title":"Oral Oncol"},{"issue":"9","key":"10.1016\/j.beha.2023.101469_bib20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","article-title":"Financial insolvency as a risk factor for early mortality among patients with cancer","volume":"34","author":"Ramsey","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2023.101469_bib21","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1200\/JOP.18.00619","article-title":"Financial toxicity after cancer in a setting with universal health coverage: a call for urgent action","volume":"15","author":"Bhoo-Pathy","year":"2019","journal-title":"J. Oncol. Pract."},{"issue":"9","key":"10.1016\/j.beha.2023.101469_bib22","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(20)30258-1","article-title":"A survey in Nepalese patients with acute leukaemia: a starting point for defining financial toxicity of cancer care in low-income and middle-income countries","volume":"7","author":"Poudyal","year":"2020","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.beha.2023.101469_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077549","article-title":"It's at a time in your life when you are most vulnerable\": a qualitative exploration of the financial impact of a cancer diagnosis and implications for financial protection in health","volume":"8","author":"Timmons","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.beha.2023.101469_bib24","series-title":"The cost burden of blood cancer care: a longitudinal analysis of commercially insured patients diagnosed with blood cancer","author":"Dieguez","year":"2018"},{"key":"10.1016\/j.beha.2023.101469_bib25","series-title":"The cost burden of blood cancer care in Medicare: a longitudinal analysis of Medicare Advantage and Fee for Service patients diagnosed with blood cancer","author":"Fitch","year":"2019"},{"issue":"22","key":"10.1016\/j.beha.2023.101469_bib26","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.beha.2023.101469_bib27","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2023.101469_bib28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.beha.2023.101469_bib29","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2023.101469_bib30","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.21873\/anticanres.11057","article-title":"Insurance status and other non-biological factors predict outcomes in acute myelogenous leukemia: analysis of data from the national cancer database","volume":"36","author":"Master","year":"2016","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.beha.2023.101469_bib31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/03007995.2016.1267615","article-title":"Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse","volume":"33","author":"Irish","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.beha.2023.101469_bib32","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bbmt.2017.02.017","article-title":"Healthcare costs and utilization for patients age 50 to 64 Years with acute myeloid leukemia treated with chemotherapy or with chemotherapy and allogeneic hematopoietic cell transplantation","volume":"23","author":"Preussler","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2023.101469_bib33","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1182\/blood-2018-99-119163","article-title":"Patient reported financial toxicity in acute leukemia","volume":"132","author":"Knight","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2023.101469_bib34","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2012-05-426783","article-title":"Economics of hematopoietic cell transplantation","volume":"120","author":"Khera","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2023.101469_bib35","first-page":"366","article-title":"The cost of hematopoietic stem-cell transplantation in the United States","volume":"10","author":"Broder","year":"2017","journal-title":"Am Health Drug Benefits"},{"issue":"7","key":"10.1016\/j.beha.2023.101469_bib36","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/annonc\/mdz140","article-title":"Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications","volume":"30","author":"Witte","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.beha.2023.101469_bib37","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cncr.30369","article-title":"Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST)","volume":"123","author":"de Souza","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2023.101469_bib38","series-title":"Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides","author":"Auletta","year":"2021"},{"issue":"8","key":"10.1016\/j.beha.2023.101469_bib39","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.bbmt.2016.05.008","article-title":"Financial hardship and patient-reported outcomes after hematopoietic cell transplantation","volume":"22","author":"Abel","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.beha.2023.101469_bib40","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.bbmt.2017.07.024","article-title":"Ascertainment of unmet needs and participation in health maintenance and screening of adult hematopoietic cell transplantation survivors followed in a formal survivorship program","volume":"23","author":"Hahn","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.beha.2023.101469_bib41","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.bbmt.2014.05.011","article-title":"Financial burden in recipients of allogeneic hematopoietic cell transplantation","volume":"20","author":"Khera","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.beha.2023.101469_bib42","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41409-018-0164-y","article-title":"Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia","volume":"53","author":"Bhatt","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.beha.2023.101469_bib43","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41409-018-0105-9","article-title":"Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia: a National Cancer Database Study","volume":"53","author":"Bhatt","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"10.1016\/j.beha.2023.101469_bib44","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1002\/cncr.26095","article-title":"Acute myeloid leukemia: how the uninsured fare","volume":"117","author":"Bradley","year":"2011","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.beha.2023.101469_bib45","first-page":"4361","article-title":"Age and gender differences in financial distress among hematopoietic cell transplant survivors","volume":"28","author":"Jones","year":"2020","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.beha.2023.101469_bib46","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/jnci\/djab013","article-title":"Medical financial hardship in survivors of adolescent and young adult cancer in the United States","volume":"113","author":"Lu","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.beha.2023.101469_bib47","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1200\/JCO.2015.62.0468","article-title":"Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors","volume":"34","author":"Yabroff","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2023.101469_bib48","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/bmt.2015.128","article-title":"Financial burden after allogeneic hematopoietic cell transplantation: a qualitative analysis from the patient's perspective","volume":"50","author":"Kim","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.beha.2023.101469_bib49","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2012.248","article-title":"Pilot study of patient and caregiver out-of-pocket costs of allogeneic hematopoietic cell transplantation","volume":"48","author":"Majhail","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"10.1016\/j.beha.2023.101469_bib50","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.2015.63.2232","article-title":"Association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer","volume":"34","author":"Lathan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2023.101469_bib51","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1634\/theoncologist.2015-0026","article-title":"Financial distress and its associations with physical and emotional symptoms and quality of life among advanced cancer patients","volume":"20","author":"Delgado-Guay","year":"2015","journal-title":"Oncol"},{"issue":"1","key":"10.1016\/j.beha.2023.101469_bib52","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/hematology.2021000292","article-title":"Psychosocial and financial issues after hematopoietic cell transplantation","volume":"2021","author":"Buchbinder","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.beha.2023.101469_bib53","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bbmt.2018.09.040","article-title":"Employment, insurance, and financial experiences of patients with chronic graft-versus-host disease in North America","volume":"25","author":"Khera","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.beha.2023.101469_bib54","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/1055-9965.EPI-17-1040","article-title":"Financial hardship after hematopoietic cell transplantation: lack of impact on survival","volume":"27","author":"Khera","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.beha.2023.101469_bib55","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/pon.3091","article-title":"Economic survivorship stress is associated with poor health-related quality of life among distressed survivors of hematopoietic stem cell transplantation","volume":"22","author":"Hamilton","year":"2013","journal-title":"Psycho Oncol"},{"key":"10.1016\/j.beha.2023.101469_bib56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12955-015-0222-8","article-title":"Factors influencing life satisfaction in acute myeloid leukemia survivors following allogeneic stem cell transplantation: a cross-sectional study","volume":"13","author":"Amler","year":"2015","journal-title":"Health Qual Life Outcome"},{"issue":"9","key":"10.1016\/j.beha.2023.101469_bib57","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.bbmt.2016.05.013","article-title":"Employment status as an indicator of recovery and function one year after hematopoietic stem cell transplantation","volume":"22","author":"Morrison","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.beha.2023.101469_bib58","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/bmt.2016.103","article-title":"Financial impact of allogeneic hematopoietic cell transplantation on patients and families over 2 years: results from a multicenter pilot study","volume":"51","author":"Denzen","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2023.101469_bib59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11764-009-0105-2","article-title":"Prospective predictors of return to work in the 5 years after hematopoietic cell transplantation","volume":"4","author":"Kirchhoff","year":"2010","journal-title":"J Cancer Surviv"},{"issue":"6","key":"10.1016\/j.beha.2023.101469_bib60","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/bmt.2014.26","article-title":"Occupational status among adult survivors following allo-SCT","volume":"49","author":"Winterling","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.beha.2023.101469_bib61","first-page":"2987","article-title":"Return to work experiences of patients treated with stem cell transplantation for a hematologic malignancy","volume":"27","author":"Persoon","year":"2019","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.beha.2023.101469_bib62","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00277-017-3097-4","article-title":"Return to work and work-related disability among AML survivors","volume":"96","author":"Samadi","year":"2017","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.beha.2023.101469_bib63","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s11136-019-02150-8","article-title":"Relationship between paid leave, financial burden, and patient-reported outcomes among employed patients who have undergone bone marrow transplantation","volume":"28","author":"Albelda","year":"2019","journal-title":"Qual Life Res"},{"issue":"5","key":"10.1016\/j.beha.2023.101469_bib64","first-page":"437","article-title":"Navigating financial toxicity in patients with cancer: a multidisciplinary management approach","volume":"72","author":"Smith","year":"2022","journal-title":"CA A Cancer J Clin"},{"issue":"21","key":"10.1016\/j.beha.2023.101469_bib65","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1002\/cncr.30940","article-title":"Setting the stage for universal financial distress screening in routine cancer care","volume":"123","author":"Khera","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.beha.2023.101469_bib66","article-title":"Development of a financial toxicity screening tool for radiation oncology: a secondary analysis of a pilot prospective patient-reported outcomes study","volume":"6","author":"Prasad","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"4","key":"10.1016\/j.beha.2023.101469_bib67","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.mayocpiqo.2020.04.004","article-title":"Developing an educational intervention to address financial hardship in cancer patients","volume":"4","author":"Khera","year":"2020","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"6","key":"10.1016\/j.beha.2023.101469_bib68","first-page":"1969","article-title":"Cancer survivorship care plans, financial toxicity, and financial planning alleviating financial distress among cancer survivors","volume":"27","author":"Coughlin","year":"2019","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.beha.2023.101469_bib69","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1200\/JOP.2013.001155","article-title":"Variation in medicaid coverage for hematopoietic cell transplantation","volume":"10","author":"Preussler","year":"2014","journal-title":"J. Oncol. Pract."},{"issue":"6","key":"10.1016\/j.beha.2023.101469_bib70","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1056\/NEJMc1004656","article-title":"Nonadherence to imatinib during an economic downturn","volume":"363","author":"Kelley","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2023.101469_bib71","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamainternmed.2014.6888","article-title":"Material need insecurities, control of diabetes mellitus, and use of health care resources: results of the Measuring Economic Insecurity in Diabetes study","volume":"175","author":"Berkowitz","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"10","key":"10.1016\/j.beha.2023.101469_bib72","doi-asserted-by":"crossref","first-page":"e1433","DOI":"10.1200\/OP.21.00124","article-title":"Levine cancer institute financial toxicity tumor board: a potential solution to an emerging problem","volume":"17","author":"Raghavan","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"10.1016\/j.beha.2023.101469_bib73","article-title":"Delivery of financial navigation services within national cancer institute-designated cancer centers","volume":"5","author":"de Moor","year":"2021","journal-title":"JNCI Cancer Spectr"},{"issue":"2","key":"10.1016\/j.beha.2023.101469_bib74","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1200\/JOP.2017.024927","article-title":"Pilot feasibility study of an oncology financial navigation program","volume":"14","author":"Shankaran","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.beha.2023.101469_bib75","series-title":"A randomized trial addressing cancer-related financial hardship through delivery of a proactive financial navigation intervention (CREDIT): swog S1912","author":"Shankaran","year":"2022"},{"issue":"1","key":"10.1016\/j.beha.2023.101469_bib76","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s13063-022-06344-3","article-title":"The Cancer Financial Experience (CAF\u00c9) study: randomized controlled trial of a financial navigation intervention to address cancer-related financial hardship","volume":"23","author":"Henrikson","year":"2022","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.beha.2023.101469_bib77","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1186\/s13063-022-06745-4","article-title":"Lessening the Impact of Financial Toxicity (LIFT): a protocol for a multi-site, single-arm trial examining the effect of financial navigation on financial toxicity in adult patients with cancer in rural and non-rural settings","volume":"23","author":"Wheeler","year":"2022","journal-title":"Trials"},{"issue":"9","key":"10.1016\/j.beha.2023.101469_bib78","doi-asserted-by":"crossref","first-page":"e1494","DOI":"10.1200\/OP.22.00056","article-title":"Financial toxicity intervention improves outcomes in patients with hematologic malignancy","volume":"18","author":"Knight","year":"2022","journal-title":"JCO Oncol Pract"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:08:18Z","timestamp":1761498498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692623000300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1521692623000300"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2023.101469","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Financial toxicity in patients with leukemia undergoing hematopoietic stem cell transplantation: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2023.101469","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101469"}}